Subscribe for $2

Subscribe for 2 $

Financial Data API

Terminal Financial Data API

Regeneron Pharmaceuticals Aktie News & Pressemeldungen

Regeneron Pharmaceuticals Eulerpool News

1/20/2025, 11:39:16 AM

Formycon erhält grünes Licht: Starke Konkurrenz für Bayer in der EU

1/13/2025, 1:52:39 PM

Truvetas genetisches Megaprojekt: Ein Milliarden-Dollar-Meilenstein in der Gesundheitsforschung

12/17/2024, 3:24:44 AM

Regeneron einigt sich im Patentstreit mit Allele über REGEN-COV

12/13/2024, 4:09:45 PM

Roche erhält EMA-Zulassung für Vabysmo in Einzeldosis-Fertigspritzen

12/3/2024, 12:10:01 PM

Regeneron belohnt Medigene mit Millionen-Meilenstein

1

2

1

2

Regeneron Pharmaceuticals Stock News

Regeneron Pharmaceuticals is being monitored by journalists and investors worldwide. We gather the latest Regeneron Pharmaceuticals news here.

January 21 ·
Yahoo
REGENERON EXPANDS PRESENCE IN CANADA BY OPENING ITS FIRST HEADQUARTERS TO BETTER SERVE NEEDS OF CANADIANS WITH SERIOUS DISEASES
January 17 ·
Yahoo
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
January 17 ·
Yahoo
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
January 16 ·
SeekingAlpha
Baird Q4 2024 International And Global Growth Fund Commentary
January 16 ·
Yahoo
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
January 16 ·
SeekingAlpha
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
January 15 ·
Yahoo
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
January 15 ·
Yahoo
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
January 15 ·
SeekingAlpha
Regeneron: Phase III Success In Skin Cancer For Libtayo
January 14 ·
Yahoo
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

1

2

1

2

Regeneron Pharmaceuticals Stock Press Releases

Regeneron Pharmaceuticals regularly publishes news on the company's website that are relevant for investors.

Access the world's leading financial data and tools

Subscribe for $2